Zevra Therapeutics, Inc. Net Change in Cash
Zevra Therapeutics, Inc. (ZVRA) reported Net Change in Cash of $82.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-05
- Zevra Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $33.19M, a 833.59% increase year-over-year.
- Zevra Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $3.56M.
- Zevra Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$200.00K.
- Zevra Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$25.29M.
- Zevra Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $28.62M.
- Zevra Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$9.26M.
- Zevra Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$22.42M.
- Zevra Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$46.88M, a 143.40% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $82.92M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $33.19M 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $28.62M 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $20.65M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $13.93M 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $3.56M 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | -$9.26M 10-K · filed 2026-03-09 | |||
| 2024-09-30 | $10.99M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | -$3.79M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | -$200.00K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$22.42M 10-K · filed 2025-03-12 | |||
| 2023-09-30 | -$22.20M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $730.00K 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$25.29M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$46.88M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | -$42.29M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | -$35.57M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$12.13M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $108.02M 10-K · filed 2023-03-07 | |||
| 2021-09-30 | $127.18M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $127.97M 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | $71.70M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $767.00K 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $1.90M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $3.00M 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | -$1.01M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | -$15.56M 10-K · filed 2021-03-12 | |||
| 2019-09-30 | -$12.11M 10-Q · filed 2020-10-30 | |||
| 2019-06-30 | -$11.32M 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | -$5.15M 10-Q · filed 2020-05-13 | |||
| 2018-12-31 | $7.15M 10-K · filed 2020-02-28 | |||
| 2018-09-30 | -$9.08M 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | $5.63M 10-Q · filed 2019-08-13 | |||
| 2018-03-31 | -$2.12M 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | -$5.89M 10-K · filed 2019-03-01 | |||
| 2017-09-30 | -$8.93M 10-Q · filed 2018-11-09 | |||
| 2017-06-30 | -$4.38M 10-Q · filed 2018-08-10 | |||
| 2017-03-31 | -$3.88M 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | -$14.46M 10-K · filed 2018-03-30 | |||
| 2016-09-30 | -$10.37M 10-Q · filed 2017-11-09 | |||
| 2015-12-31 | $22.06M 10-K · filed 2018-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |